SGLT2i Plus GLP-1 Supported by ESC in Diabetes with High CVD Risk.

Published Date: 29 Aug 2023

A GLP-1 receptor agonist and an SGLT2 inhibitor should be used concurrently to treat people with type 2 diabetes and established cardiovascular disease, according to new ESC guidelines.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot